Yttrium ⁹⁰Y chloride

The pharmacodynamic properties of yttrium (⁹⁰Y)-labelled medicinal products prepared by radiolabelling with yttrium (⁹⁰Y) chloride, prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled. Refer to the Summary of Product Characteristics/package leaflet of the particular medicinal product to be radiolabelled.

The pharmacokinetic properties of yttrium (⁹⁰Y)-labelled medicinal products prepared by radiolabelling with Yttrium (⁹⁰Y) chloride, prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled.

In the rat, following intravenous administration, yttrium (⁹⁰Y) chloride is rapidly cleared from the blood. At 1 and 24 hours, blood radioactivity decreases from 11.0% to 0.14% of the administered activity. The two main organs where yttrium (⁹⁰Y) chloride distributes are the liver and bones. In the liver, 18% of the injected activity is taken up 5 min after injection. Liver uptake decreases then to 8.4% 24 hours after injection. In bone, percentage of injected activity increases from 3.1% at 5 min to 18% at 6 hours and then decreases with time. Faecal and urinary elimination is slow: about 31 % of the administered activity is eliminated in 15 days.

The toxicological properties of yttrium (⁹⁰Y)-labelled medicinal products prepared by radiolabelling with yttrium (⁹⁰Y) chloride prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled.

There are no data available on the toxicity of yttrium (⁹⁰Y) chloride nor on its effects on reproduction in animals or its mutagenic or carcinogenic potential.